[144] Vicarious Surgical Inc. SEC Filing

Rhea-AI Filing Summary

Vicarious Surgical Inc. (RBOT) filing a Form 144 notifies proposed sale of 40,427 shares of Class A common stock through two brokers for planned sale on 09/22/2025. The shares break down as 32,469 with Interactive Brokers (aggregate market value $189,943.65) and 7,958 with UBS Financial Services (aggregate market value $46,554.30), against 5,298,253 shares outstanding. The reporting person acquired a total of 45,339 shares over multiple dates via distributions and vesting from 2021–2024. In the prior three months the filer sold 4,912 shares for gross proceeds of $31,540.00. The signer certifies no undisclosed material adverse information.

Positive

• Transparent disclosure of broker names, exact share counts, acquisition dates and methods consistent with Rule 144 requirements
• Planned sale size is small relative to shares outstanding (~0.76%), reducing likelihood of major market impact
• Acquisitions are documented as distributions and vested restricted stock, showing the shares originate from prior compensation/distributions

Negative

• Insider selling activity including 4,912 shares sold in August (gross proceeds $31,540.00) could be viewed negatively by some investors
• No additional context on purpose of sales or whether trading plan (Rule 10b5-1) applies is provided in the filing

Insights

Securities Analyst

TL;DR: Routine Rule 144 notice; proposed sale equals ~0.76% of outstanding shares, likely non-material to market on its own.

The Form 144 reports a planned disposition of 40,427 Class A shares to be executed through two brokers on 09/22/2025. Relative to the reported 5,298,253 shares outstanding, this represents roughly 0.76% dilution if sold into the market, which is typically not market-moving for a company of this share base. The filing also documents acquisition history (distributions and vested restricted stock) totaling 45,339 shares, indicating the sales are of previously received compensation and distributions rather than new issuance. Recent August sales (4,912 shares for $31,540) show the filer has been executing smaller disposals already.

Corporate Governance Expert

TL;DR: Disclosure is standard and complies with Rule 144; the filing includes the usual insider certifications.

The notice contains required details: broker names, share counts, acquisition dates and methods, and recent sales over the past three months. The filer affirms there is no undisclosed material adverse information and references the criminal penalties for misstatement. From a governance perspective this is a routine transparency exercise by an insider disposing of previously acquired equity via distributions and vested awards. No executives' departures, new plans, or governance changes are disclosed in this filing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common Stock	Interactive Broker LLC One Pickwick Plaza Greeenwich CT 06830	32469	189943.65	5298253	09/22/2025	NYSE
Class A Common Stock	UBS Financial Services Inc. 1285 6th Ave New York NY 10019	7958	46554.30	5298253	09/22/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common Stock	07/13/2022	Stock distribution from the D8 Sponsor LLC	D8 Sponsor LLC			34048	07/13/2022	Distribution In-kind
Class A Common Stock	06/02/2023	Stock distribution from a fund in which the Reporting Person is an investor	a PIPE investor			3333	06/02/2023	Distribution In-kind
Class A Common Stock	06/10/2024	Restricted Stock Vested	Vicarious Surgical Inc			3299	06/10/2024	Restricted Stock Vested
Class A Common Stock	06/01/2023	Restricted Stock Vested	Vicarious Surgical Inc			2200	06/01/2023	Restricted Stock Vested
Class A Common Stock	06/01/2022	Restricted Stock Vested	Vicarious Surgical Inc			1268	06/01/2022	Restricted Stock Vested
Class A Common Stock	11/23/2021	Restricted Stock Vested	Vicarious Surgical Inc			321	11/23/2021	Restricted Stock Vested
Class A Common Stock	11/23/2021	Restricted Stock Vested	Vicarious Surgical Inc			870	11/23/2021	Restricted Stock Vested

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Tang Donald F C/O Vicarious Surgical Inc 78 Fourth Avenue Waltham MA 02451	Class A Common Stock	08/26/2025	2753	18436.00
Tang Donald F C/O Vicarious Surgical Inc 78 Fourth Avenue Waltham MA 02451	Class A Common Stock	08/20/2025	2059	12436.00
Tang Donald F C/O Vicarious Surgical Inc 78 Fourth Avenue Waltham MA 02451	Class A Common Stock	08/19/2025	100	668.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for Vicarious Surgical Inc. (RBOT) disclose?

The filing notifies a proposed sale of 40,427 Class A shares to occur on 09/22/2025, lists two brokers, acquisition history, and recent sales in August totaling 4,912 shares for $31,540.00.

How many shares outstanding does the filing report for RBOT?

The filing reports 5,298,253 Class A shares outstanding.

What brokers will execute the proposed RBOT sales?

The shares are scheduled to be sold through Interactive Broker LLC and UBS Financial Services Inc.

What is the aggregate market value of the proposed RBOT sale?

The two lots show aggregate market values of $189,943.65 and $46,554.30, totaling $236,497.95.

What is the origin of the shares being sold according to the filing?

Shares were acquired via stock distributions from D8 Sponsor LLC and a PIPE fund, and via restricted stock vesting from Vicarious Surgical Inc. between 2021 and 2024, totaling 45,339 acquired shares.